Biote Corp (BTMD) Q1 2026 Earnings Call Transcript

Why It Matters

The results underscore Biote's transition toward a higher‑margin supplement business and aggressive commercial investment, positioning it for revenue acceleration despite short‑term procedural headwinds. Investors will watch whether the sales expansion and regulatory tailwinds translate into the projected 2026 growth targets.

Key Takeaways

• Revenue fell 6.9% year‑over‑year
• Supplement sales rose 16% via e‑commerce
• Gross margin slipped to 68% after recall charge
• Sales team grew to 90, targeting 120 in 2026
• 2026 outlook: >$190M revenue, >$38M adjusted EBITDA

Pulse Analysis

Biote Corp’s Q1 earnings reveal a company at a strategic inflection point. While total revenue contracted, the 16% surge in dietary supplement sales highlights a successful pivot toward a more resilient, e‑commerce‑driven revenue stream. This shift reduces reliance on clinic‑based procedures, which suffered a 13% decline due to higher attrition and a voluntary recall of hormone pellets. The recall, though modest in monetary impact, pressured gross margins, emphasizing the importance of supply‑chain control and the potential volatility of third‑party manufacturing.

The firm’s aggressive commercial expansion is a cornerstone of its 2026 outlook. By increasing the sales force from roughly 60 to over 90 reps—and targeting 120—Biote aims to accelerate new clinic openings and deepen practitioner relationships. Full‑capacity training sessions signal strong practitioner recruitment, a leading indicator of future procedure volume. Coupled with a planned technology platform upgrade, these investments are designed to improve practitioner retention, streamline certification, and ultimately boost procedural revenue in the second half of the year.

Regulatory developments add another layer of optimism. The FDA’s removal of black‑box warnings for certain hormone‑replacement therapies creates a favorable environment for Biote’s core offerings, potentially expanding market acceptance and patient demand. When combined with the company’s robust cash position—$24.1 million in cash and $35.2 million operating cash flow—the firm is well‑placed to fund its growth initiatives without immediate financing pressure. Stakeholders should monitor margin recovery, the effectiveness of the sales expansion, and the pace of procedural revenue rebound as key determinants of whether Biote can meet its ambitious >$190 million revenue and >$38 million adjusted EBITDA targets for 2026.